Evolving Therapeutics for Lifelong Protection

Autonomous Therapeutics is at the forefront of developing a novel class of RNA technology known as encrypted RNA (encRNA). This innovative approach aims to create first-in-class medicines that are not only target-activated but also variant-proof, addressing a wide range of health challenges from influenza to various forms of cancer. The company's focus on encRNA technology allows for the design of therapeutics that can effectively respond to specific targets within the body, enhancing the precision and efficacy of treatments.

In addition to its work on cancer and influenza, Autonomous Therapeutics has also been recognized for its potential in combating viral infections, particularly SARS-CoV-2. The company has received significant funding, including a $1 million award from the BLUE KNIGHT™ Resident QuickFire Challenge, to advance its encrypted RNA platform. This funding is aimed at developing a next-generation prophylactic that promises single-dose, long-lasting protection against all variants of SARS-CoV-2, showcasing the versatility and potential impact of their RNA-based technologies in public health.

United States

Autonomous Therapeutics is a synthetic immunology company developing artificial immune systems that are personalized and variant-proof.

Encrypted RNA™ is a new class of RNA that enables variant-proof immunity against infectious diseases and cancers.

Autonomous Therapeutics

Company Details